Literature DB >> 16433034

Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals.

Toshihiko Hori1, Masao Nakano, Yasuo Kimura, Kazuhisa Murakami.   

Abstract

The pharmacokinetic properties of doripenem following 20 mg/kg i.v. infusion were studied in various laboratory animals. The concentrations of doripenem in plasma, urine and tissue samples were determined by bioassay. Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively. In monkeys, with co-administration of probenecid, the mean AUC(0-infinity) of doripenem increased about 2.2 times and urinary excretion was delayed slightly. In mice, the doripenem level was highest in the blood plasma, followed by the kidney, liver, lung, heart and spleen. These doripenem levels in various tissues rapidly decreased and no accumulation was observed. Serum protein binding rates (%) of doripenem were 25.2 in mice, 35.2 in rats, 11.8 in rabbits, 10.2 in dogs, 6.1 in monkeys and 8.1 in humans, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433034

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  17 in total

1.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

2.  Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.

Authors:  M G Vossen; L Ehmann; S Pferschy; A Maier-Salamon; M Haidinger; C Weiser; J M Wenisch; K Saria; C Kajahn; S Jilch; R Lemmerer; M Bécède; M Zeitlinger; C Kloft; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.

Authors:  Jamese J Hilliard; John L Melton; LeRoy Hall; Darren Abbanat; Jeffrey Fernandez; Christine K Ward; Rachel A Bunting; A Barron; A Simon Lynch; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers.

Authors:  Bernhard Burian; Markus Zeitlinger; Oliver Donath; Gottfried Reznicek; Robert Sauermann
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

5.  In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.

Authors:  Aryun Kim; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

6.  In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

7.  In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Darren Abbanat; Wenyan Zhang; John L Melton; Colleen M Santoro; Robert K Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

8.  Pharmacodynamic variability beyond that explained by MICs.

Authors:  Rachel L Soon; Neang S Ly; Gauri Rao; Lance Wollenberg; Kuo Yang; Brian Tsuji; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 9.  Doripenem: a review of its use in the treatment of bacterial infections.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.